查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371920

噬菌體療法的全球市場，到 2030 年的市場預測：按產品、類型、目標細菌、適應症、給藥途徑、給藥配銷通路、用途、最終用戶、地區進行全球分析

Bacteriophage Therapy Market Forecasts to 2030 - Global Analysis By Product, Type, Targeted Bacteria, Disease Indication, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球噬菌體治療市場規模為 4,659 萬美元，預計 2030 年將達到 8,090 萬美元，年複合成長率為 8.2%。

噬菌體是僅攻擊和殺死細菌的病毒。噬菌體是最常見的生物體，可以對抗和消滅具有多重抗藥性的細菌。當所有其他抗生素都失效時，噬菌體可以消除引起感染疾病的細菌，使醫護人員得以挽救生命。此外，噬菌體正在被研究作為抗生素的替代療法。這種治療方法使用病毒將遺傳物質注入細菌中，使它們能夠利用宿主的機器進行繁殖。

根據美國疾病管制與預防中心 (CDC) 的數據，歐洲每年約有 33,000 人受到抗生素抗藥性細菌感染疾病的影響。預計全球抗生素抗藥性將增加，對噬菌體產生巨大需求。

抗生素抗藥性增加

在人類醫學和農業中過度使用抗生素會產生嚴重後果，包括抗生素抗藥性增加。這種令人震驚的趨勢導致了抗生素抗藥性超級細菌的出現，並迫切需要噬菌體療法等替代療法。此外，噬菌體是天然存在的病毒，能夠靶向並消滅細菌，使其成為對抗這些抗藥性病原體的有前途的武器。研究人員正在研究如何使用噬菌體混合物和專門設計的噬菌體有效地瞄準和消除這些頑固的細菌菌株。

臨床資料不足和法規障礙

要讓法規相信噬菌體療法的安全性和有效性是很困難的。這是因為能夠提供足夠臨床證據的大規模隨機對照試驗並不多。然而，新治療方法的法規環境非常嚴格，需要大量的臨床資料，這使得獲得產品核准既耗時又昂貴。在克服這些挑戰的同時，開發人員還必須解決臨床試驗中使用的噬菌體製劑的一致性和品質問題。

研發投資

快速增加的研發成本推動了噬菌體療法的創新。噬菌體工程、噬菌體文庫的創建以及噬菌體療法與免疫療法和抗生素等其他治療方法的結合都是活躍的研究主題。此外，這種動態環境不僅使治療工具箱多樣化，而且促進了對噬菌體生物學及其臨床應用的深入理解。

法規問題和缺乏可靠的臨床資料

缺乏大規模、一流的臨床資料是噬菌體治療市場的最大威脅之一。由於噬菌體療法的臨床試驗相對較少，法規可能會推遲核准並增加開發成本。此外，法規機構核准新治療方法需要強力的臨床證據。對於開發商來說，適應新治療方法的法規環境可能既困難又耗時。

COVID-19 的影響

噬菌體治療市場受到了 COVID-19大流行的各種影響。雖然噬菌體和其他替代療法由於人們對感染疾病和抗生素抗藥性的日益關注而受到更多關注，但這場大流行也將更多的資源、注意力和研究工作集中在了 COVID-19 上。供應鏈問題推遲了噬菌體療法的臨床試驗和研究，並導致生產中斷。儘管如此，這場大流行病還是引起了人們對多種治療選擇的需求的關注，特別是醫療機構中持續存在的細菌威脅，以及在大流行後時代加速採用噬菌體療法治療抗生素抗藥性感染疾病的潛力。是。

在預測期內，尿道感染領域預計將是最大的。

尿道感染（UTI）領域佔據噬菌體治療市場的最大佔有率。每年，數百萬人患有尿道結石，這是最常見的細菌感染疾病之一。此外，由於導致尿道結石的抗生素抗藥性菌株數量不斷增加，噬菌體療法已成為有前途的選擇。噬菌體療法可有效針對特定的泌尿道致病細菌，尿道結石。尿道結石的複發性和抗生素在預防復發方面的限制進一步增加了基於噬菌體的治療方法在該市場的市場潛力。

預計抗生素發現領域在預測期內年複合成長率最高

在噬菌體治療市場，抗菌藥物的發現正以最高的年複合成長率成長。世界各地對抗生素抗藥性的擔憂日益增加，導致尋找新抗菌藥物的資金和研究不斷增加。噬菌體靶向並消滅抗生素抗藥性細菌的能力引起了藥物研發配合措施的極大興趣。此外，不斷探索噬菌體發現和創造新抗菌藥物的潛力是該市場快速成長的關鍵驅動力，是解決嚴重的抗藥性感染疾病問題的迫切需求的解決方案。

佔比最大的地區：

預計北美地區將擁有噬菌體療法最高的市場佔有率。造成這一優勢的因素有很多，包括強大的醫療基礎設施、抗生素抗藥性細菌引起的感染疾病發生率高、研發方面的大量投資以及支持性的法規環境。北美由於該地區生物技術和製藥行業的蓬勃發展以及噬菌體療法在臨床實踐中的使用不斷增加而引領市場。此外，透過學術機構、製藥公司和政府機構之間的合作，噬菌體療法在北美迅速擴張，目前佔據最大的市場佔有率。

複合年複合成長率最高的地區

在全球噬菌體治療市場中，亞太地區的年複合成長率最高。這種快速擴張是多種要素共同作用的結果，包括抗生素抗藥性感染疾病的流行、醫療保健行業的擴張以及公眾對噬菌體療法潛在優勢的認知不斷提高。亞太地區正在大力投資研發，重點是建立高效的生產技術和擴大臨床應用。此外，當地學術機構、外國製藥公司和當地生物技術公司之間的合作正在促進創新並擴大市場。

免費客製化服務

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究來源
    • 主要研究來源
    • 二次研究來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球噬菌體治療市場：按產品

  • 噬菌體益生菌
  • 噬菌體療法
  • 其他產品

第6章 全球噬菌體治療市場：依類型

  • 赫里尼克
  • 溶原性
  • 其他類型

第7章 全球噬菌體治療市場：依目標細菌

  • 大腸桿菌
  • 金黃色葡萄球菌
  • 鏈球菌
  • 銅綠假單胞菌
  • 沙門氏菌
  • 其他目標細菌

第8章 全球噬菌體治療市場：依疾病適應症

  • 尿道感染
  • 慢性中耳炎
  • 拔牙
  • 慢性潰瘍性大腸炎
  • 骨感染疾病
  • 傷口和皮膚感染疾病
  • 囊性纖維化
  • 其他疾病適應症

第9章 全球噬菌體治療市場：依給藥途徑

  • 口服
  • 局部的
  • 胃腸外的

第10章 全球噬菌體治療市場：依配銷通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第11章全球噬菌體治療市場：依用途

  • 皮膚感染疾病的治療
  • 消化內科
  • 預防傷口
  • 呼吸道感染疾病的治療
  • 泌尿生殖感染疾病的治療
  • 診斷
  • 抗生素藥物藥物研發
  • 老兵專用醫藥
  • 其他用途

第12章全球噬菌體治療市場：依最終用戶分類

  • 醫院/診所
  • 學術研究組織/機構
  • 其他最終用戶

第13章全球噬菌體治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東/非洲

第14章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第15章公司簡介

  • InnoPhage Ltd
  • Eliava Biopreparations Ltd.
  • Adaptive Phage Therapeutics, Inc
  • Nextbiotics
  • Armata Pharmaceuticals Inc.
  • Enbiotix Inc.
  • Eligo Bioscience SA
  • BiomX Ltd.
  • Phagomed Biopharma GmbH
  • Intodeworld Inc.
  • Phi Therapeutics
  • ContraFect Corporation
  • Locus Biosciences Inc.
  • Intralytix Inc.
  • PhagePro Inc.
  • Pherecydes Pharma
  • TechnoPhage SA
Product Code: SMRC23977

According to Stratistics MRC, the Global Bacteriophage Therapy Market is accounted for $46.59 million in 2023 and is expected to reach $80.90 million by 2030 growing at a CAGR of 8.2% during the forecast period. Bacteriophages are viruses that only attack and kill bacteria. They are among the most prevalent biological organisms capable of battling and eliminating bacteria with multiple drug resistances. Phages can eliminate the bacteria causing an infection when all other antibiotics have failed to treat it, enabling medical professionals to save a life. Additionally, bacteriophages are being investigated as an alternative to antibiotics. In this therapy, viruses are used to inject bacteria with their genetic material so that the bacteria can use the machinery of their hosts to grow.

According to the Centers for Disease Control and Prevention (CDC), antibiotic-resistant bacterial infections affect approximately 33 000 people in Europe each year. Antibiotic resistance is predicted to increase globally, creating considerable demand for bacteriophages.

Market Dynamics:

Driver:

Increasing antibiotic resistance

The overuse and abuse of antibiotics in both human medicine and agriculture have serious consequences, including the rise in antibiotic resistance. Antibiotic-resistant superbugs have emerged as a result of this worrying trend, necessitating the urgent need for alternative therapies like bacteriophage therapy. Moreover, bacteriophages are naturally occurring viruses that target and destroy bacteria, making them a promising weapon against these pathogens that are drug-resistant. Researchers are investigating how to effectively target and get rid of these tough bacterial strains using phage cocktails and specially created phages.

Restraint:

Insufficient clinical data and regulatory obstacles

It is difficult to persuade regulatory agencies of the safety and effectiveness of bacteriophage therapy because there aren't many large-scale, randomized controlled trials that can provide sufficient clinical evidence. However, it may take longer to get a product approved for the market and cost more money because of the strict regulatory environment for new therapies and the requirement for extensive clinical data. While overcoming these challenges, developers must also address issues with the consistency and quality of phage preparations used in clinical trials.

Opportunity:

Investments in research and development

Innovation in bacteriophage therapy is accelerating as a result of the surge in R&D spending. Phage engineering, the creation of phage libraries, and the combination of phage therapy with other therapeutic modalities like immunotherapies or antibiotics are all topics of active research. Moreover, this dynamic environment encourages a deeper comprehension of phage biology and its clinical applications, in addition to diversifying the therapeutic toolbox.

Threat:

Regulatory issues and a lack of robust clinical data

Lack of large-scale, top-notch clinical data is one of the biggest threats to the bacteriophage therapy market. Because there have been relatively few clinical trials for bacteriophage therapy, regulatory agencies may delay approvals and raise development costs. Furthermore, regulatory agencies need strong clinical evidence to approve new therapies. It can be challenging and time-consuming for developers to navigate the regulatory environment for novel therapies.

COVID-19 Impact:

The bacteriophage therapy market has been affected in different ways by the COVID-19 pandemic. Although bacteriophages and other alternative therapies have received more attention due to the increased focus on infectious diseases and antibiotic resistance, the pandemic has also focused more resources, attention, and research efforts on COVID-19. Due to supply chain issues, bacteriophage therapy clinical trials and research were delayed, and some production interruptions happened. Despite this, the pandemic brought attention to the need for a wider range of treatment options, which may hasten the adoption of bacteriophage therapy in the post-pandemic era, particularly for persistent bacterial threats in healthcare settings and antibiotic-resistant infections.

The Urinary Tract Infections segment is expected to be the largest during the forecast period

In the market for bacteriophage therapy, the urinary tract infections (UTIs) segment commands the largest share. Each year, millions of people experience UTIs, which are among the most prevalent bacterial infections. Moreover, bacteriophage therapy has become a promising alternative due to the rise in antibiotic-resistant strains that cause UTIs. It is a compelling option for both simple and complex UTIs due to its effectiveness in targeting particular uropathogenic bacteria. Further boosting the market potential for bacteriophage-based treatments in this market are the recurrent nature of UTIs and the limitations of antibiotics in preventing relapses.

The Antimicrobial Drug Discovery segment is expected to have the highest CAGR during the forecast period

In the market for bacteriophage therapy, antimicrobial drug discovery is growing at the highest CAGR. There has been an increase in funding and research into finding new antimicrobial agents as a result of the growing concern about antibiotic resistance around the world. The ability of bacteriophages to target and destroy bacteria that are resistant to antibiotics has attracted a lot of interest in drug discovery efforts. Furthermore, the ongoing investigation of bacteriophages potential for locating and creating novel antimicrobial remedies-solutions that are urgently required to address the mounting problem of drug-resistant infections-is the primary driver of this market's rapid growth.

Region with largest share:

The largest market share for bacteriophage therapy is anticipated to be in the North American region. A number of elements, such as a strong healthcare infrastructure, a high incidence of infections caused by bacteria resistant to antibiotics, significant investments in research and development, and a supportive regulatory environment, can be credited for this dominance. The region's thriving biotechnology and pharmaceutical sectors, along with the growing use of bacteriophage therapy in clinical settings, place North America as a market leader. Additionally, bacteriophage therapy has expanded more quickly in North America thanks to partnerships between academic institutions, pharmaceutical companies, and governmental organizations, where it now accounts for the largest market share.

Region with highest CAGR:

In the global market for bacteriophage therapy, Asia-Pacific is growing at the highest CAGR. This rapid expansion is a result of a number of factors, including the heavy prevalence of infections that are resistant to antibiotics, the expanding healthcare industry, and growing public awareness of the potential advantages of bacteriophage therapy. With a focus on creating efficient production techniques and extending clinical applications, the Asia-Pacific region is seeing significant investments in research and development. Furthermore, collaborations between local academic institutions, pharmaceutical firms from abroad, and regional biotechnology companies are promoting innovation and expanding the market.

Key players in the market:

Some of the key players in Bacteriophage Therapy market include: InnoPhage Ltd, Eliava Biopreparations Ltd., Adaptive Phage Therapeutics, Inc, Nextbiotics, Armata Pharmaceuticals Inc., Enbiotix Inc., Eligo Bioscience SA, BiomX Ltd., Phagomed Biopharma GmbH, Intodeworld Inc., Phi Therapeutics, ContraFect Corporation, Locus Biosciences Inc., Intralytix Inc., PhagePro Inc., Pherecydes Pharma and TechnoPhage SA.

Key Developments:

In May 2023, Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center. Researchers at the IPTC have discovered several phages that have exceptionally broad coverage against antibiotic resistant bacteria.

In January 2023, Armata Pharmaceuticals, Inc., a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc, Armata's largest shareholder.

In July 2022, Micro biome firm BiomX is to continue collaborating with pharma giants Boehringer Ingelheim in a partnership that looks to identify biomarkers for inflammatory bowel disease (IBD). BiomX Ltd. The agreement, the second one between the two firms, uses BiomX's XMarker micro biome-based biomarker discovery platform to aid in identifying IBD-linked pathogenic bacterium. Additional agreement terms see BiomX receive research payments with Boehringer able to negotiate an exclusive right to biomarkers discovered under the collaboration.

Products Covered:

  • Phage Probiotics
  • Phage Therapeutic
  • Other Products

Types Covered:

  • Lytic
  • Lysogenic
  • Other Types

Targeted Bacterias Covered:

  • Escherichia Coli
  • Staphylococcus Aureus
  • Streptococcus
  • Pseudomonas Aeruginosa
  • Salmonella
  • Other Targeted Bacterias

Disease Indications Covered:

  • Urinary Tract Infections
  • Chronic Otitis
  • Dental Extraction
  • Chronic Ulcerative Colitis
  • Bone Infection
  • Wound and Skin Infections
  • Cystic Fibrosis
  • Other Disease Indications

Route of Administrations Covered:

  • Oral
  • Topical
  • Parenteral

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Applications Covered:

  • Skin Infection Treatment
  • Gastroenterology
  • Wound Prophylaxis
  • Respiratory Infections Treatment
  • Urogenital Infection Treatment
  • Diagnostic
  • Antimicrobial Drug Discovery
  • Veterinary Medicines
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Academic Research Organizations & Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bacteriophage Therapy Market, By Product

  • 5.1 Introduction
  • 5.2 Phage Probiotics
  • 5.3 Phage Therapeutic
  • 5.4 Other Products

6 Global Bacteriophage Therapy Market, By Type

  • 6.1 Introduction
  • 6.2 Lytic
  • 6.3 Lysogenic
  • 6.4 Other Types

7 Global Bacteriophage Therapy Market, By Targeted Bacteria

  • 7.1 Introduction
  • 7.2 Escherichia Coli
  • 7.3 Staphylococcus Aureus
  • 7.4 Streptococcus
  • 7.5 Pseudomonas Aeruginosa
  • 7.6 Salmonella
  • 7.7 Other Targeted Bacterias

8 Global Bacteriophage Therapy Market, By Disease Indication

  • 8.1 Introduction
  • 8.2 Urinary Tract Infections
  • 8.3 Chronic Otitis
  • 8.4 Dental Extraction
  • 8.5 Chronic Ulcerative Colitis
  • 8.6 Bone Infection
  • 8.7 Wound and Skin Infections
  • 8.8 Cystic Fibrosis
  • 8.9 Other Disease Indications

9 Global Bacteriophage Therapy Market, By Route of Administration

  • 9.1 Introduction
  • 9.2 Oral
  • 9.3 Topical
  • 9.4 Parenteral

10 Global Bacteriophage Therapy Market, By Distribution Channel

  • 10.1 Introduction
  • 10.2 Hospital Pharmacies
  • 10.3 Retail Pharmacies
  • 10.4 Online Pharmacies

11 Global Bacteriophage Therapy Market, By Application

  • 11.1 Introduction
  • 11.2 Skin Infection Treatment
  • 11.3 Gastroenterology
  • 11.4 Wound Prophylaxis
  • 11.5 Respiratory Infections Treatment
  • 11.6 Urogenital Infection Treatment
  • 11.7 Diagnostic
  • 11.8 Antimicrobial Drug Discovery
  • 11.9 Veterinary Medicines
  • 11.10 Other Applications

12 Global Bacteriophage Therapy Market, By End User

  • 12.1 Introduction
  • 12.2 Hospitals & Clinics
  • 12.3 Academic Research Organizations & Institutes
  • 12.4 Other End Users

13 Global Bacteriophage Therapy Market, By Geography

  • 13.1 Introduction
  • 13.2 North America
    • 13.2.1 US
    • 13.2.2 Canada
    • 13.2.3 Mexico
  • 13.3 Europe
    • 13.3.1 Germany
    • 13.3.2 UK
    • 13.3.3 Italy
    • 13.3.4 France
    • 13.3.5 Spain
    • 13.3.6 Rest of Europe
  • 13.4 Asia Pacific
    • 13.4.1 Japan
    • 13.4.2 China
    • 13.4.3 India
    • 13.4.4 Australia
    • 13.4.5 New Zealand
    • 13.4.6 South Korea
    • 13.4.7 Rest of Asia Pacific
  • 13.5 South America
    • 13.5.1 Argentina
    • 13.5.2 Brazil
    • 13.5.3 Chile
    • 13.5.4 Rest of South America
  • 13.6 Middle East & Africa
    • 13.6.1 Saudi Arabia
    • 13.6.2 UAE
    • 13.6.3 Qatar
    • 13.6.4 South Africa
    • 13.6.5 Rest of Middle East & Africa

14 Key Developments

  • 14.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 14.2 Acquisitions & Mergers
  • 14.3 New Product Launch
  • 14.4 Expansions
  • 14.5 Other Key Strategies

15 Company Profiling

  • 15.1 InnoPhage Ltd
  • 15.2 Eliava Biopreparations Ltd.
  • 15.3 Adaptive Phage Therapeutics, Inc
  • 15.4 Nextbiotics
  • 15.5 Armata Pharmaceuticals Inc.
  • 15.6 Enbiotix Inc.
  • 15.7 Eligo Bioscience SA
  • 15.8 BiomX Ltd.
  • 15.9 Phagomed Biopharma GmbH
  • 15.10 Intodeworld Inc.
  • 15.11 Phi Therapeutics
  • 15.12 ContraFect Corporation
  • 15.13 Locus Biosciences Inc.
  • 15.14 Intralytix Inc.
  • 15.15 PhagePro Inc.
  • 15.16 Pherecydes Pharma
  • 15.17 TechnoPhage SA

List of Tables

  • Table 1 Global Bacteriophage Therapy Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bacteriophage Therapy Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Bacteriophage Therapy Market Outlook, By Phage Probiotics (2021-2030) ($MN)
  • Table 4 Global Bacteriophage Therapy Market Outlook, By Phage Therapeutic (2021-2030) ($MN)
  • Table 5 Global Bacteriophage Therapy Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 6 Global Bacteriophage Therapy Market Outlook, By Type (2021-2030) ($MN)
  • Table 7 Global Bacteriophage Therapy Market Outlook, By Lytic (2021-2030) ($MN)
  • Table 8 Global Bacteriophage Therapy Market Outlook, By Lysogenic (2021-2030) ($MN)
  • Table 9 Global Bacteriophage Therapy Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 10 Global Bacteriophage Therapy Market Outlook, By Targeted Bacteria (2021-2030) ($MN)
  • Table 11 Global Bacteriophage Therapy Market Outlook, By Escherichia Coli (2021-2030) ($MN)
  • Table 12 Global Bacteriophage Therapy Market Outlook, By Staphylococcus Aureus (2021-2030) ($MN)
  • Table 13 Global Bacteriophage Therapy Market Outlook, By Streptococcus (2021-2030) ($MN)
  • Table 14 Global Bacteriophage Therapy Market Outlook, By Pseudomonas Aeruginosa (2021-2030) ($MN)
  • Table 15 Global Bacteriophage Therapy Market Outlook, By Salmonella (2021-2030) ($MN)
  • Table 16 Global Bacteriophage Therapy Market Outlook, By Other Targeted Bacterias (2021-2030) ($MN)
  • Table 17 Global Bacteriophage Therapy Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 18 Global Bacteriophage Therapy Market Outlook, By Urinary Tract Infections (2021-2030) ($MN)
  • Table 19 Global Bacteriophage Therapy Market Outlook, By Chronic Otitis (2021-2030) ($MN)
  • Table 20 Global Bacteriophage Therapy Market Outlook, By Dental Extraction (2021-2030) ($MN)
  • Table 21 Global Bacteriophage Therapy Market Outlook, By Chronic Ulcerative Colitis (2021-2030) ($MN)
  • Table 22 Global Bacteriophage Therapy Market Outlook, By Bone Infection (2021-2030) ($MN)
  • Table 23 Global Bacteriophage Therapy Market Outlook, By Wound and Skin Infections (2021-2030) ($MN)
  • Table 24 Global Bacteriophage Therapy Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
  • Table 25 Global Bacteriophage Therapy Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 26 Global Bacteriophage Therapy Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 27 Global Bacteriophage Therapy Market Outlook, By Oral (2021-2030) ($MN)
  • Table 28 Global Bacteriophage Therapy Market Outlook, By Topical (2021-2030) ($MN)
  • Table 29 Global Bacteriophage Therapy Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 30 Global Bacteriophage Therapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 31 Global Bacteriophage Therapy Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 32 Global Bacteriophage Therapy Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 33 Global Bacteriophage Therapy Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 34 Global Bacteriophage Therapy Market Outlook, By Application (2021-2030) ($MN)
  • Table 35 Global Bacteriophage Therapy Market Outlook, By Skin Infection Treatment (2021-2030) ($MN)
  • Table 36 Global Bacteriophage Therapy Market Outlook, By Gastroenterology (2021-2030) ($MN)
  • Table 37 Global Bacteriophage Therapy Market Outlook, By Wound Prophylaxis (2021-2030) ($MN)
  • Table 38 Global Bacteriophage Therapy Market Outlook, By Respiratory Infections Treatment (2021-2030) ($MN)
  • Table 39 Global Bacteriophage Therapy Market Outlook, By Urogenital Infection Treatment (2021-2030) ($MN)
  • Table 40 Global Bacteriophage Therapy Market Outlook, By Diagnostic (2021-2030) ($MN)
  • Table 41 Global Bacteriophage Therapy Market Outlook, By Antimicrobial Drug Discovery (2021-2030) ($MN)
  • Table 42 Global Bacteriophage Therapy Market Outlook, By Veterinary Medicines (2021-2030) ($MN)
  • Table 43 Global Bacteriophage Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 44 Global Bacteriophage Therapy Market Outlook, By End User (2021-2030) ($MN)
  • Table 45 Global Bacteriophage Therapy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 46 Global Bacteriophage Therapy Market Outlook, By Academic Research Organizations & Institutes (2021-2030) ($MN)
  • Table 47 Global Bacteriophage Therapy Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.